Related Experiment Video
Updated: Mar 19, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Subtype-specific patterns of molecular mutations in acute myeloid leukemia
D Rose1, T Haferlach1, S Schnittger1
1MLL Munich Leukemia Laboratory, Munich, Germany.
Abstract:
Acute myeloid leukemia (AML) can be grouped into morphologically or genetically defined subtypes. Today, the AML phenotype-genotype associations, that is, FAB/WHO (French-American-British/World Health Organization) definitions and recurrent molecular mutations, are not fully understood. Therefore, we evaluated the impact of molecular mutations on the AML differentiation stage by molecular profiling of 4373 adult de novo AML patients in 7 cytomorphological subtypes. We investigated mutations in 20 genes, including myeloid transcription factors (CEBPA, RUNX1), tumor suppressors (TP53, WT1), DNA modifiers (DNMT3A, IDH1/2, TET2), chromatin modifiers (ASXL1, MLL), signal transduction genes (FLT3, KRAS, NRAS) and NPM1. The most frequently mutated genes per cytomorphological subtype were RUNX1 in M0 (43%), NPM1 in M1 (42%), DNMT3A in M2 (26%), NPM1 in M4 (57%), M5a (49%) and M5b (70%) and TP53 in M6 (36%). Although some gene mutations were frequent in several cytomorphological subtypes, a series of associations of co-occurring mutations with distinct phenotypes were identified for molecularly defined subcohorts. FLT3, NPM1 and WT1 mutations were associated with an immature phenotype in myeloblastic AML, whereas other combinations involving ASXL1, RUNX1, MLL-PTD, CEBPA or KRAS were more frequent in myeloblastic AML with maturation. Within the NPM1 mutated subcohort, ASXL1 mutations were significantly associated with a monoblastic differentiation and DNMT3A mutations with a monocytic phenotype.
Insights
Molecular mutations significantly impact Acute Myeloid Leukemia (AML) subtypes. This study reveals specific gene mutations correlating with distinct AML differentiation stages and phenotypes, aiding in better classification and understanding of AML progression.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute Myeloid Leukemia (AML) classification relies on morphology and genetics, but phenotype-genotype associations remain incompletely understood.
- Existing French-American-British (FAB)/World Health Organization (WHO) definitions and recurrent molecular mutations require further clarification regarding their interplay.
Purpose of the Study:
- To investigate the impact of molecular mutations on the differentiation stage of adult de novo Acute Myeloid Leukemia (AML).
- To identify specific genotype-phenotype associations within cytomorphological AML subtypes through comprehensive molecular profiling.
Main Methods:
- Molecular profiling of 4373 adult de novo AML patients across 7 cytomorphological subtypes.
- Analysis of mutations in 20 key genes, including transcription factors, tumor suppressors, DNA/chromatin modifiers, and signal transduction genes.
Main Results:
- Identified frequent mutations per subtype: RUNX1 in M0, NPM1 in M1, DNMT3A in M2, NPM1 in M4/M5a/M5b, and TP53 in M6.
- Established associations between specific mutations (FLT3, NPM1, WT1) and immature myeloblastic AML phenotypes.
- Linked other mutations (ASXL1, RUNX1, MLL-PTD, CEBPA, KRAS) to myeloblastic AML with maturation.
- Within NPM1-mutated AML, ASXL1 mutations correlated with monoblastic differentiation, and DNMT3A mutations with monocytic phenotype.
Conclusions:
- Molecular mutations play a critical role in defining AML differentiation stages and phenotypes.
- Specific mutation patterns offer insights into distinct AML subcohorts, potentially refining diagnostic and prognostic approaches.
- Further research into these genotype-phenotype associations can advance personalized AML treatment strategies.
Related Concept Videos
02:21Cancers Originate from Somatic Mutations in a Single Cell
01:39Mutations
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...